Aims: The global prevalence rate of hepatitis C virus (HCV) infection is 2.5 %. Approximately 21.3 million patients infected with HCV are living in Eastern Mediterranean countries. Chronic HCV patients taking interferon with ribavirin from different ethnic groups have different probabilities of reaching a sustained virological response (SVR). There are many factors, such as HCV genotype, age, gender, body weight, IL-28B single-nucleotide polymorphism, concomitant disease and liver function enzymes. The purpose of this study was to model the probability of achieving a sustained virological response in individual patients, taking into consideration various predictive factors. Methods: Total of 120 subjects was interviewed and was subjective to routine laboratory investigation and abdominal ultrasound. Forty-six were excluded due to co-infection with HBC or HIV, decompensated liver disease, drug dependence, alcoholic, autoimmune disease, pregnancy, cardiac disease, age above 70 years, and poorly controlled diabetic patients. Only 72 patients with chronic HCV who received pegylated interferon and ribavirin (Peg-IFN/RBV) in Tripoli Center Hospital (TCH) in Tripoli, Libya from 2014 to 2015 were included. Quantitative HCVRNA was assessed before the treatment and at week 1, week 4, week12, week 24, week 48 and week 72 to detect whether the patient achieved SVR. Multivariate logistic regression analysis was performed to identify variables associated with treatment response. Results: At 24 weeks after the end of combination therapy, the overall SVR was detected in 49 (68%). However, 53 (73%) of patients achieved end treatment response (ETR). Moreover, the SVR was significantly higher in patients with genotype 1b and 3a (100%) than in patients with genotype 1a and 2 (28% and 57.1% respectively). However, there was no significant difference between patients who given INFa2a and INF a2b (P=0.75). IL28B CC haplotype patient, the viral load less than 600,000 IU.ml-1(matches 5.7 logs) and the body weight < 80kg, non-detectable HCV-RNA level at week four, and genotype of the HCV were factors that predict good response for Peg-IFN/RBV combined therapy (P<0.05). However, age and gender were not a significant predictive factor. Conclusions: This prediction model uses easily determined variables for a personalized estimate of the probability of SVR with Peg-IFN/RBV, allowing to identify patients who may benefit from conventional therapy.